China's healthcare authorities have declined to include Pfizer's COVID-19 treatment drug in a national reimbursement list that would have allowed patients to get it at a cheaper price throughout the country, saying it was too expensive.
If you are already a subscriber
OR sign-up for a trial access here
Note that your comment may be edited or removed in the future, and that your comment may appear alongside the original article on websites other than this one.
more »
Brought to you by